SCHEMBL18998524

SCHEMBL18998524

NCc1cc(-c2cccc(NC(=O)C3CC3)c2)ccc1N1CCC[C@@H]1C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 1/20 0.45
▸ ALPL P05186 1/20 0.43
▸ ALPI P09923 1/20 0.43
▸ ALPG P10696 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ F10 P00742 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ACKR3 P25106 3/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ TP53BP1 Q12888 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ AR P10275 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18998577 0.92 HPGD (0.44) CFDALPLALPIALPGKMT2A
SCHEMBL18998518 0.87 ALPI (0.44) ALPLALPIALPGKMT2ASMN1; SMN2
SCHEMBL18998529 0.87 ALPI (0.44) ALPLALPIALPGKMT2ASMN1; SMN2
SCHEMBL18998527 0.86 KMT2A (0.43) CFDALPLALPIALPGKMT2A
SCHEMBL18998748 0.83 AR (0.56) CFDALPLALPIALPGKMT2A
SCHEMBL18998517 0.83 KMT2A (0.47) ALPLALPIALPGKMT2ASMN1; SMN2
SCHEMBL18998555 0.79 KMT2A (0.43) ALPLALPIALPGKMT2AF10
SCHEMBL18998550 0.78 MAPK1 (0.43) ALPLALPIALPGKMT2AF10
SCHEMBL18998549 0.78 MAPK1 (0.43) ALPLALPIALPGKMT2AF10
SCHEMBL18998532 0.75 KMT2A (0.43) ALPLALPIALPGKMT2AF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174713-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2017-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174713-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS TBKBP1, TNKS1BP1, TNKS CFD 4825/4885ALPL 3230/4885ALPI 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback